Commission President Ursula von der Leyen presented today in Paris the main elements of "Choose Europe", a new policy initiative to ensure Europe ...

The Trump administration’s unprecedented $500 million grant for a broadly protective flu shot has confounded vaccine and ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This article aimed to identify ...

Andrew Nixon, spokesman for Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., announced on ...

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA c ...

Ludwig-Maximilians-Universität München-led researchers have induced a greater than 60% reduction in seizure frequency in a ...

Marley Mansour was diagnosed in early 2023 after years of unanswered questions. The rare genetic disorder affects protein ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Novavax, Inc.  has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, ...

Matica Biotechnology, a specialized contract development and manufacturing organization (CDMO) for cell and gene therapies (CGT), has entered into a strategic partnership with the National Center for ...

PTC Therapeutics, Inc. today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. The study met its primary endpoint of ...